Peptides and the Blood-Brain Barrier

Enhancing Peptide Bioavailability to the Brain

Richard D. Egleton, Ken A. Witt, Thomas P Davis

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

The growth of the biotech industry over the last decade has resulted in an exponential increase in the number of drugs developed to treat neurological disorders. Despite the obvious importance of peptides in modulating physiological function, the number of peptide neuropharmaceuticals remains small. The primary reason for this is the presence of the blood-brain barrier (BBB). The BBB is a unique membranous barrier, which regulates the delivery of substances to the brain. Peptides generally have limited transport across the BBB for a number of reasons, based principally on the biochemical nature of the peptides. Peptides are generally metabolized enzymatically and are taken up avidly by peripheral organs, thus further reducing availability to be transported to the brain. This chapter describes a number of strategies that have proven effective in the experimental delivery of peptides to the central nervous system, which can be utilized for neuropharmaceutical development.

Original languageEnglish (US)
Title of host publicationBlood-Spinal Cord and Brain Barriers in Health and Disease
PublisherElsevier Inc.
Pages107-115
Number of pages9
ISBN (Print)9780080528229, 9780126390117
DOIs
StatePublished - Nov 21 2003

Fingerprint

Blood-Brain Barrier
Biological Availability
Peptides
Brain
Nervous System Diseases
Industry
Central Nervous System
Growth
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Medicine(all)
  • Neuroscience(all)

Cite this

Egleton, R. D., Witt, K. A., & Davis, T. P. (2003). Peptides and the Blood-Brain Barrier: Enhancing Peptide Bioavailability to the Brain. In Blood-Spinal Cord and Brain Barriers in Health and Disease (pp. 107-115). Elsevier Inc.. https://doi.org/10.1016/B978-012639011-7/50015-2

Peptides and the Blood-Brain Barrier : Enhancing Peptide Bioavailability to the Brain. / Egleton, Richard D.; Witt, Ken A.; Davis, Thomas P.

Blood-Spinal Cord and Brain Barriers in Health and Disease. Elsevier Inc., 2003. p. 107-115.

Research output: Chapter in Book/Report/Conference proceedingChapter

Egleton, RD, Witt, KA & Davis, TP 2003, Peptides and the Blood-Brain Barrier: Enhancing Peptide Bioavailability to the Brain. in Blood-Spinal Cord and Brain Barriers in Health and Disease. Elsevier Inc., pp. 107-115. https://doi.org/10.1016/B978-012639011-7/50015-2
Egleton RD, Witt KA, Davis TP. Peptides and the Blood-Brain Barrier: Enhancing Peptide Bioavailability to the Brain. In Blood-Spinal Cord and Brain Barriers in Health and Disease. Elsevier Inc. 2003. p. 107-115 https://doi.org/10.1016/B978-012639011-7/50015-2
Egleton, Richard D. ; Witt, Ken A. ; Davis, Thomas P. / Peptides and the Blood-Brain Barrier : Enhancing Peptide Bioavailability to the Brain. Blood-Spinal Cord and Brain Barriers in Health and Disease. Elsevier Inc., 2003. pp. 107-115
@inbook{104b1636c2ed433cabe1242c1203fa90,
title = "Peptides and the Blood-Brain Barrier: Enhancing Peptide Bioavailability to the Brain",
abstract = "The growth of the biotech industry over the last decade has resulted in an exponential increase in the number of drugs developed to treat neurological disorders. Despite the obvious importance of peptides in modulating physiological function, the number of peptide neuropharmaceuticals remains small. The primary reason for this is the presence of the blood-brain barrier (BBB). The BBB is a unique membranous barrier, which regulates the delivery of substances to the brain. Peptides generally have limited transport across the BBB for a number of reasons, based principally on the biochemical nature of the peptides. Peptides are generally metabolized enzymatically and are taken up avidly by peripheral organs, thus further reducing availability to be transported to the brain. This chapter describes a number of strategies that have proven effective in the experimental delivery of peptides to the central nervous system, which can be utilized for neuropharmaceutical development.",
author = "Egleton, {Richard D.} and Witt, {Ken A.} and Davis, {Thomas P}",
year = "2003",
month = "11",
day = "21",
doi = "10.1016/B978-012639011-7/50015-2",
language = "English (US)",
isbn = "9780080528229",
pages = "107--115",
booktitle = "Blood-Spinal Cord and Brain Barriers in Health and Disease",
publisher = "Elsevier Inc.",

}

TY - CHAP

T1 - Peptides and the Blood-Brain Barrier

T2 - Enhancing Peptide Bioavailability to the Brain

AU - Egleton, Richard D.

AU - Witt, Ken A.

AU - Davis, Thomas P

PY - 2003/11/21

Y1 - 2003/11/21

N2 - The growth of the biotech industry over the last decade has resulted in an exponential increase in the number of drugs developed to treat neurological disorders. Despite the obvious importance of peptides in modulating physiological function, the number of peptide neuropharmaceuticals remains small. The primary reason for this is the presence of the blood-brain barrier (BBB). The BBB is a unique membranous barrier, which regulates the delivery of substances to the brain. Peptides generally have limited transport across the BBB for a number of reasons, based principally on the biochemical nature of the peptides. Peptides are generally metabolized enzymatically and are taken up avidly by peripheral organs, thus further reducing availability to be transported to the brain. This chapter describes a number of strategies that have proven effective in the experimental delivery of peptides to the central nervous system, which can be utilized for neuropharmaceutical development.

AB - The growth of the biotech industry over the last decade has resulted in an exponential increase in the number of drugs developed to treat neurological disorders. Despite the obvious importance of peptides in modulating physiological function, the number of peptide neuropharmaceuticals remains small. The primary reason for this is the presence of the blood-brain barrier (BBB). The BBB is a unique membranous barrier, which regulates the delivery of substances to the brain. Peptides generally have limited transport across the BBB for a number of reasons, based principally on the biochemical nature of the peptides. Peptides are generally metabolized enzymatically and are taken up avidly by peripheral organs, thus further reducing availability to be transported to the brain. This chapter describes a number of strategies that have proven effective in the experimental delivery of peptides to the central nervous system, which can be utilized for neuropharmaceutical development.

UR - http://www.scopus.com/inward/record.url?scp=84942931206&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84942931206&partnerID=8YFLogxK

U2 - 10.1016/B978-012639011-7/50015-2

DO - 10.1016/B978-012639011-7/50015-2

M3 - Chapter

SN - 9780080528229

SN - 9780126390117

SP - 107

EP - 115

BT - Blood-Spinal Cord and Brain Barriers in Health and Disease

PB - Elsevier Inc.

ER -